Insulet expands Omnipod reach with Calm mindfulness partnership for diabetes care
Jul 14, 2026, 3:09 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Strategic partnership enhances brand equity, patient engagement, and adherence potential; while immediate revenue impact is unclear, increased adoption and payer acceptance could follow if the program improves outcomes.
AI summary
What happened, with direct paths to the underlying reporting
Insulet (PODD) and Calm announce a global Mind in Range Collection offering free mindfulness resources for the diabetes community, including a sleep story narrated by Lila Moss. The partnership underscores the emotional burden of diabetes and positions Omnipod as part of holistic care, potentially boosting patient engagement and brand equity with near-term visibility and longer-term adherence benefits.
Insulet partners with Calm to launch Mind in Range Collection for diabetes care.
Free mindfulness tools include meditations, breathing, and a sleep story narrated by Lila Moss.
Collection targets diabetes-related stress; global data cite high burnout and poor sleep.
Global rollout across Calm and Omnipod channels starts today.
Insulet cites 80% burnout among people with diabetes as rationale.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Insulet cut its annual sales-growth outlook, citing softer demand in the US Omnipod franchise in the second half of 2026. The guidance reduction triggered a premarket drop of more…
FDA recall covers Omnipod 5, DASH, and Eros pods due to cannula tear causing insulin leakage and under-delivery, risking high blood sugar and DKA. As of May 20, 24 serious injurie…
Grabar Law Office has launched a shareholder investigation into Insulet (PODD) for alleged fiduciary breaches, coinciding with the company’s Omnipod manufacturing corrections anno…
An appeals court overturned Insulet's $452 million verdict against EOFlow over insulin-pump trade secrets, reducing Insulet's near-term liabilities. The ruling injects appellate u…